Monitoring HF exacerbation and cardiac resynchronization therapy performance

• US 8,090,443 B2
• Filed: 09/15/2008
• Issued: 01/03/2012
• Est. Priority Date: 09/15/2008
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Inventors: Min, Xiaoyi, Syed, Zaffer
• Primary Examiner(s): Schaetzle, Kennedy
• Application Number:
  US12/210,880
• Publication Number:
  US 20100069987A1
• Time in Patent Office: 1,205 Days
• Field of Search: None
• US Class Current: 607/17
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36585 controlled by two or more physical parameters
• CPC Class Codes: A61N 1/3682 with a variable atrioventricular delay

Abstract

An exemplary method includes delivering a cardiac resynchronization therapy using an atrio-ventricular delay parameter and an interventricular delay parameter, measuring an atrio-ventricular conduction delay, measuring an interventricular conduction delay, assessing heart failure and/or cardiac resynchronization therapy performance based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay and determining at least one of an atrio-ventricular delay parameter value and an interventricular delay parameter value based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay. Other exemplary technologies are also disclosed.

Claims

1. A method comprising:

delivering a cardiac resynchronization therapy that comprises an atrio-ventricular delay parameter and an interventricular delay parameter;

measuring an intrinsic atrio-ventricular conduction delay;

measuring an intrinsic interventricular conduction delay;

assessing heart failure status based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay; and

adjusting at least one of the atrio-ventricular delay parameter value and the interventricular delay parameter value based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay.

2. The method of claim 1 further comprising assessing cardiac resynchronization therapy performance based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay.

3. The method of claim 1 further comprising measuring an intrinsic P wave width and using the measured P wave width in the assessing heart failure.

4. The method of claim 1 further comprising measuring an intrinsic P wave width and using the measured P wave width in the determining at least one of an atrio-ventricular delay parameter value and an interventricular delay parameter value.

5. The method of claim 1 further comprising measuring a paced A wave width and using the measured A wave width in the assessing heart failure.

6. The method of claim 1 further comprising measuring a paced A wave width and using the measured A wave width in the determining at least one of an atrio-ventricular delay parameter value and an interventricular delay parameter value.

7. The method of claim 1 further comprising measuring pacing latency and using the measured pacing latency in the assessing heart failure.

8. The method of claim 1 further comprising measuring one or more evoked response characteristics and using the one or more measured characteristics in the assessing heart failure.

9. The method of claim 1 further comprising measuring impedance and using the measured impedance in the assessing heart failure.

10. The method of claim 1 further comprising transmitting information from the cardiac resynchronization therapy device to another device.

11. The method of claim 10 wherein the other device comprises a computing device configured to establish a communication link to the cardiac resynchronization therapy device and to operate in a patient environment.

12. A method comprising:

delivering a cardiac resynchronization therapy that comprises an atrio-ventricular delay parameter and an interventricular delay parameter;

measuring an atrio-ventricular conduction delay;

measuring an interventricular conduction delay;

assessing cardiac resynchronization therapy performance based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay; and

determining at least one of an atrio-ventricular delay parameter value and an interventricular delay parameter value based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay.

13. The method of claim 12 further comprising measuring pacing latency and using the measured pacing latency in the assessing cardiac resynchronization therapy performance.

14. The method of claim 12 further comprising measuring one or more evoked response characteristics and using the one or more measured characteristics in the assessing cardiac resynchronization therapy performance.

15. The method of claim 12 further comprising measuring impedance and using the measured impedance in the assessing cardiac resynchronization therapy performance.

16. An implantable medical device comprising:

stimulation circuitry that delivers cardiac resynchronization therapy that comprises an atrio-ventricular delay parameter and an interventricular delay parameter;

sensing circuitry that measures an intrinsic atrio-ventricular conduction delay and an intrinsic interventricular conduction delay;

assessment circuitry that assesses heart failure status based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay; and

wherein the stimulation circuitry adjusts at least one of the atrio-ventricular delay parameter value and the interventricular delay parameter value based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay.

17. The implantable medical device of claim 16 wherein the sensing circuitry measures pacing latency;

and wherein the assessment circuitry uses the measured pacing latency to assess heart failure status.

18. The implantable medical device of claim 16 wherein the sensing circuitry measures one or more evoked response characteristics;

and wherein the assessment circuitry uses the one or more measured characteristics to assess heart failure status.

19. The implantable medical device of claim 16 wherein the sensing circuitry measures impedance;

and wherein the assessment circuitry uses the measured impedance to assess heart failure status.

20. The implantable medical device of claim 16 and further comprising telemetry circuitry to transmit information from the implantable medical device to another device.